GLP-1 Dose Escalation Guide UK: How Fast to Go Up and When to Pause

The standard dose escalation schedule printed on your Wegovy, Ozempic, or Mounjaro leaflet exists for a reason: it minimises side effects and gives your body time to adapt to each dose level. But the pharmaceutical schedule is not the only valid approach — and for a significant proportion of patients, following it rigidly leads to avoidable dropout.

Understanding the difference between standard titration and flexible titration — and knowing when your body is telling you to pause — is the practical knowledge that gets patients to an effective maintenance dose without unnecessary misery.

Standard Escalation Schedules

Wegovy (Semaglutide 2.4mg)

| Week | Dose | |------|------| | 1-4 | 0.25mg weekly | | 5-8 | 0.5mg weekly | | 9-12 | 1.0mg weekly | | 13-16 | 1.7mg weekly | | 17+ | 2.4mg weekly (maintenance) |

The standard schedule reaches maintenance dose at week 17. Most people tolerate this, but nausea — particularly at the 1.0mg and 1.7mg steps — is common. The STEP 1 trial reported nausea in 44% of participants (versus 16% placebo).

Mounjaro (Tirzepatide)

| Week | Dose | |------|------| | 1-4 | 2.5mg weekly | | 5-8 | 5mg weekly | | 9-12 | 7.5mg weekly | | 13-16 | 10mg weekly | | 17-20 | 12.5mg weekly | | 21+ | 15mg weekly (maximum) |

Mounjaro has a longer escalation to maximum dose — 21 weeks to reach 15mg. In practice, many patients find an effective maintenance dose at 5-10mg without needing to escalate further.

Ozempic (Semaglutide 1mg — diabetes dose)

| Week | Dose | |------|------| | 1-4 | 0.25mg weekly | | 5+ | 0.5mg (initial maintenance) | | After 4 weeks at 0.5mg | Increase to 1mg if needed |

Ozempic is primarily a type 2 diabetes medication; its weight loss use is off-label at the 1mg dose. The lower doses mean less weight loss than Wegovy 2.4mg, but also typically milder side effects.

The Case for Flexible Titration

The standard schedules were designed for clinical trial conditions — regular monitoring, motivated participants, close follow-up. Real-world prescribing is different. Patients have variable side effect thresholds, different starting body weights, and different life circumstances that affect how they manage the early weeks.

A 2026 study published in Frontiers in Endocrinology examined what happens when patients are given control over their own dose escalation within a clinical framework.

A dropout rate falling from 19% to 2% is not a marginal improvement — it is the difference between a drug that works and a drug that gets abandoned. The weight loss outcomes were comparable between the two groups, meaning that going slower does not compromise the final result.

What Flexible Titration Looks Like in Practice

Flexible titration means staying at each dose step until your side effects are manageable, rather than advancing on a fixed calendar schedule. In practice:

• If you are comfortable at a dose step with minimal nausea, you advance on schedule (or even slightly early, with prescriber agreement)
• If you have moderate nausea, vomiting, or diarrhoea at a dose step, you pause at that dose for an extra 2-4 weeks before attempting to advance
• If you have severe side effects, you step back down to the previous dose and stabilise before trying again

This is not the same as stopping the drug. It is a strategic pause.

Not all prescribers offer formal flexible titration — it requires your prescriber to be willing to write prescriptions at non-standard intervals. Ask directly: "Can we manage my escalation based on how I'm tolerating each step, rather than advancing on a fixed 4-week schedule?" Most UK private prescribers will accommodate this; NHS pathways can be more rigid.

Signs That Mean You Should Pause

These are the signals that justify staying at your current dose rather than advancing:

GI symptoms that affect daily function. Occasional nausea is expected and acceptable. Nausea that prevents eating, causes repeated vomiting, or interferes with work or sleep is a signal to pause. Advancing your dose in this state will make it significantly worse.

Persistent nausea beyond week 4 of a dose step. Nausea should diminish within 2-4 weeks of a dose increase. If you are still vomiting or severely nauseated at week 5 of a particular dose, your body needs more time.

Significant dehydration. Repeated vomiting or diarrhoea combined with GLP-1-related appetite suppression can cause dehydration rapidly. Signs include dark urine, dizziness on standing, headache, and muscle cramps. Pause and rehydrate before advancing.

Severe constipation. GLP-1 drugs slow gastric motility. Some patients develop significant constipation, especially when not drinking enough fluids. This can be painful and — in extreme cases — lead to bowel complications. Address constipation before escalating.

Heart rate elevation. A modest increase in resting heart rate (5-10 bpm) is a known effect of semaglutide. A large, sustained increase — particularly if accompanied by palpitations — should be discussed with your prescriber before advancing.

Signs You Can Advance (or May Not Need To)

Comfortable at current dose. If you feel well at your current dose with minimal side effects and good appetite suppression, you can advance on schedule.

Weight loss has plateaued at current dose. If you have been on a dose for 12+ weeks with no further weight loss and no significant side effects, advancing to the next dose is likely appropriate.

Appetite suppression is insufficient. Some patients find that hunger returns towards the end of each week at lower doses. This usually resolves with dose escalation.

You have reached maintenance and are responding well. Not everyone needs to reach the maximum dose. If you are losing weight consistently and tolerating your current dose well, there is no automatic reason to advance to the highest dose. Discuss with your prescriber whether escalating further adds meaningful benefit for you.

The "One Step Back" Strategy

If you advance a dose and find the side effects unmanageable, you have two options:

1. Ride it out — side effects may improve within 2-3 weeks
2. Step back down to the previous dose, stabilise, then try advancing again after 4-6 weeks

The second approach is more commonly recommended for severe reactions. Stepping back is not failure. It is good dose management. The only outcome that matters is reaching a dose you can sustain long-term — the route to get there is a secondary consideration.

Missed Doses

Missing a single injection of Wegovy or Mounjaro is not catastrophic. The guidance is:

• If it is within 5 days of the scheduled dose: inject as soon as possible
• If it is 5 or more days since the scheduled dose: skip and inject on the next scheduled day

Do not double-dose. Missing more than 2 consecutive weeks may require your prescriber to restart the titration from a lower dose to avoid severe side effects.

Practical Tips for Managing the Escalation Period

Timing of injection. Some patients find that injecting in the evening means peak nausea occurs overnight while they are asleep, reducing daytime disruption. Others prefer morning injections. Experiment to find what works for you.

Eating during peak nausea. Small, bland, low-fat meals are tolerated better than large or rich meals. Avoid alcohol during the early weeks of each dose step.

Hydration. Drink consistently throughout the day. GLP-1 drugs suppress thirst in some patients — set reminders to drink water if you are not doing so naturally.

Ginger. Clinical data on ginger for nausea is modest but consistent. Ginger tea or ginger chews are low-risk and worth trying.

For more detailed nausea management strategies, see /guides/nausea-management-semaglutide-uk.

For a full side effects guide, see /guides/glp1-side-effects-uk.

Finding a Prescriber Who Will Manage Escalation Properly

Flexible, responsive dose management requires a prescriber who is available for ongoing dialogue — not just an initial consultation. This is one of the key differentiators between higher-quality and lower-quality UK GLP-1 services.

When evaluating a service, ask:

• Can I message or call if I have side effects between consultations?
• Can the dose schedule be adjusted without a full consultation fee?
• How quickly can the prescriber respond to dose-related questions?

For a comparison of UK GLP-1 prescribing services, see /guides/best-glp1-prescriber-uk-2026.